Aclaris Therapeutics 11/6/2024 Earnings Report $2.72 -0.05 (-1.81%) (As of 12/20/2024 05:31 PM ET) Earnings HistoryForecast Aclaris Therapeutics EPS ResultsActual EPS-$0.11Consensus EPS -$0.08Beat/MissMissed by -$0.03One Year Ago EPSN/AAclaris Therapeutics Revenue ResultsActual Revenue$4.35 millionExpected Revenue$8.31 millionBeat/MissMissed by -$3.96 millionYoY Revenue GrowthN/AAclaris Therapeutics Announcement DetailsQuarterDate11/6/2024TimeBefore Market OpensConference Call ResourcesACRS Earnings History Wall Street Icon: “You must get on the right side of this thing” (Ad)I created one of the first quantitative analysis-based stock picking systems long before "quants" became a thing on Wall Street… leading Forbes to call me "King of the Quants." I'm writing to you today because my system has recently uncovered a market phenomenon I haven't seen in 30 years.This market shakeup is going to be much more intense. Aclaris Therapeutics Earnings HeadlinesBrokerages Set Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Price Target at $8.80December 22 at 1:45 AM | americanbankingnews.comAclaris Therapeutics: Promising Pipeline and Strong Financial Outlook Drive Buy RatingDecember 18, 2024 | markets.businessinsider.comVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold $3 billion of Amazon… it’s why Nvidia’s CEO just sold $713 million... and it’s why Zuckerberg just sold $1.3 billion in Meta stock. The financial establishment doesn’t want you to know about this… but a controversial new documentary just pulled back the curtain and exposed what’s really going on. It’s called The Final Frontier.December 22, 2024 | Porter & Company (Ad)Stifel Nicolaus Remains a Hold on Aclaris Therapeutics (ACRS)December 17, 2024 | markets.businessinsider.comAclaris Therapeutics Announces New Employee Stock Grants Under 2024 Inducement PlanDecember 5, 2024 | msn.comAclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)December 3, 2024 | globenewswire.comSee More Aclaris Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Aclaris Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aclaris Therapeutics and other key companies, straight to your email. Email Address About Aclaris TherapeuticsAclaris Therapeutics (NASDAQ:ACRS) a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.View Aclaris Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles History Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of Earnings Upcoming Earnings Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
